Literature DB >> 32571811

In Vitro Activities of Ravuconazole and Isavuconazole against Dematiaceous Fungi.

Hailin Zheng1,2, Nana Song1, Huan Mei1, Jiacheng Dong1, Dongmei Li3, Xiaofang Li4,2, Weida Liu4,2,5.   

Abstract

The in vitro activities of 11 antifungals against 84 dematiaceous fungi were tested. For most tested fungal species, the MIC values of ravuconazole and isavuconazole were lower than those obtained with itraconazole, voriconazole, and posaconazole. Ravuconazole and isavuconazole appear to be more efficient against most dematiaceous fungal infections than the other triazoles. However, some pigmented fungi, such as Bipolaris spicifera and Veronaea botryosa, remain more susceptible to other triazoles or to echinocandins.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  antifungal susceptibility; dematiaceous fungi; isavuconazole; ravuconazole

Mesh：

Substances：

Year:  2020        PMID： 32571811      PMCID： PMC7449202          DOI： 10.1128/AAC.00643-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  28 in total

1.  Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole.

Authors:  M A Pfaller; A Espinel-Ingroff; R N Jones
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

2.  In Vitro Ravuconazole Susceptibility of Anthropophilic Dermatophyte Strains Isolated from Japanese Patients.

Authors:  Rui Kano; Junichiro Hiruma; Maki Yokota; Hiromitsu Noguchi; Midori Hase; Hiroshi Kamata; Kazutoshi Harada; Masataro Hiruma
Journal:  Jpn J Infect Dis       Date:  2019-12-25       Impact factor: 1.362

3.  In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Emilia Mellado; Guillermo Garcia-Effron; Araceli Monzon; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

4.  In vitro susceptibility of dematiaceous fungi to nine antifungal agents determined by two different methods.

Authors:  Hailin Zheng; Yun He; Siyue Kan; Dongmei Li; Guixia Lv; Yongnian Shen; Huan Mei; Xiaofang Li; Weida Liu
Journal:  Mycoses       Date:  2019-02-20       Impact factor: 4.377

5.  ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi.

Authors:  A Chowdhary; J F Meis; J Guarro; G S de Hoog; S Kathuria; M C Arendrup; S Arikan-Akdagli; M Akova; T Boekhout; M Caira; J Guinea; A Chakrabarti; E Dannaoui; A van Diepeningen; T Freiberger; A H Groll; W W Hope; E Johnson; M Lackner; K Lagrou; F Lanternier; C Lass-Flörl; O Lortholary; J Meletiadis; P Muñoz; L Pagano; G Petrikkos; M D Richardson; E Roilides; A Skiada; A M Tortorano; A J Ullmann; P E Verweij; O A Cornely; M Cuenca-Estrella
Journal:  Clin Microbiol Infect       Date:  2014-04       Impact factor: 8.067

Review 6.  Chromoblastomycosis.

Authors:  Paweł M Krzyściak; Małgorzata Pindycka-Piaszczyńska; Michał Piaszczyński
Journal:  Postepy Dermatol Alergol       Date:  2014-10-22       Impact factor: 1.837

Review 7.  Role of isavuconazole in the treatment of invasive fungal infections.

Authors:  Dustin T Wilson; V Paul Dimondi; Steven W Johnson; Travis M Jones; Richard H Drew
Journal:  Ther Clin Risk Manag       Date:  2016-08-03       Impact factor: 2.423

8.  Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.

Authors:  George R Thompson; Adrian Rendon; Rodrigo Ribeiro Dos Santos; Flavio Queiroz-Telles; Luis Ostrosky-Zeichner; Nkechi Azie; Rochelle Maher; Misun Lee; Laura Kovanda; Marc Engelhardt; Jose A Vazquez; Oliver A Cornely; John R Perfect
Journal:  Clin Infect Dis       Date:  2016-05-11       Impact factor: 9.079

9.  Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis.

Authors:  Rachel Harrington; Edward Lee; Hongbo Yang; Jin Wei; Andrew Messali; Nkechi Azie; Eric Q Wu; James Spalding
Journal:  Adv Ther       Date:  2016-12-02       Impact factor: 3.845

10.  A five-year survey of dematiaceous fungi in a tropical hospital reveals potential opportunistic species.

Authors:  Su Mei Yew; Chai Ling Chan; Kok Wei Lee; Shiang Ling Na; Ruixin Tan; Chee-Choong Hoh; Wai-Yan Yee; Yun Fong Ngeow; Kee Peng Ng
Journal:  PLoS One       Date:  2014-08-06       Impact factor: 3.240
View more
  2 in total

1.  Screening the pandemic response box identified benzimidazole carbamates, Olorofim and ravuconazole as promising drug candidates for the treatment of eumycetoma.

Authors:  Wilson Lim; Bertrand Nyuykonge; Kimberly Eadie; Mickey Konings; Juli Smeets; Ahmed Fahal; Alexandro Bonifaz; Matthew Todd; Benjamin Perry; Kirandeep Samby; Jeremy Burrows; Annelies Verbon; Wendy van de Sande
Journal:  PLoS Negl Trop Dis       Date:  2022-02-04

Review 2.  Phaeohyphomycosis in China.

Authors:  Yun He; Hai-Lin Zheng; Huan Mei; Gui-Xia Lv; Wei-da Liu; Xiao-Fang Li
Journal:  Front Cell Infect Microbiol       Date:  2022-06-13       Impact factor: 6.073
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.